Caplacizumab bulk supplier for pharma manufacturers

Caplacizumab 10mg Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 10mg

Reference Brands: Cablivi (USA/EU)

Caplacizumab is a nanobody-based medication that targets von Willebrand factor (vWF), preventing platelet aggregation and microthrombi formation. It’s used alongside plasma exchange and immunosuppression to treat acquired thrombotic thrombocytopenic purpura (aTTP) in adults, helping reduce clot formation and disease recurrence.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Caplacizumab — third party manufacturing & bulk supply

Caplacizumab 10mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Caplacizumab is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Caplacizumab listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Caplacizumab →

Back to Listing

Frequently Asked Questions

Caplacizumab is listed as Injection in 10mg. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Caplacizumab is referenced against Cablivi (USA/EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.